首页> 外文期刊>Gastroenterology Insights >Helicobacter pylori clarithromycin resistance assessment: are gastric antral biopsies sufficient?
【24h】

Helicobacter pylori clarithromycin resistance assessment: are gastric antral biopsies sufficient?

机译:幽门螺杆菌克拉霉素耐药性评估:胃窦活检是否足够?

获取原文
获取外文期刊封面目录资料

摘要

Gastric biopsy ssampling could affect accuracy of Helicobacter pylori clarithromycin resistance assessment due to coexistence of susceptible and resistant strains ( i.e . heteroresistance) either in same gastric site (intraniche) or in two different gastric sites (interniche). This study aimed to assess differences in the H. pylori clarithromycin resistance prevalence in relation to the gastric biopsy sampling by using Taqman-real time polymerase chain reaction (PCR). The study enrolled 137 patients. Primary clarithromycin resistance was observed in 15 isolates exclusively in antrum, in 7 cases exclusively in gastric body, and in 3 patients in both gastric sites. The overall prevalence of clarithromycin resistance was 13.1% by using exclusively antral biopsies, and 18.2% by using biopsies from both gastric sites. Moreover, intra-niche heteroresistance was observed in 19 (76%) out of 25 patients harbouring resistant strains. Our data found a heterogeneous distribution of resistant H. pylori strains in the stomach. Similarly to culture, gastric biopsies from both antrum and gastric body are needed to increase the accuracy of PCR-based methods for clarithromycin resistance assessment.
机译:胃活检取样可能影响幽门螺杆菌克拉霉素耐药性评估的准确性,因为易感菌株和耐药菌株(异源耐药性)在同一胃部位(intraniche)或在两个不同胃部位(interniche)共存。这项研究旨在通过使用Taqman实时聚合酶链反应(PCR)评估幽门螺杆菌克拉霉素耐药率相对于胃活检样本的差异。该研究招募了137名患者。原发性克拉霉素耐药性出现在胃窦的15个分离株,胃体的7例和两个胃部位的3例。仅胃窦活检对克拉霉素耐药的总体患病率为13.1%,而胃两个部位的活检则为18.2%。此外,在25例具有耐药菌株的患者中,有19例(76%)观察到了小生境内异抗性。我们的数据发现胃中耐药幽门螺杆菌菌株的异质分布。与培养相似,需要从胃窦和胃体进行胃活检,以提高基于PCR的克拉霉素耐药性评估方法的准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号